MedElevator
Войти в исследования Canadian liver journal · 2026
Quality of life and self-reported stigma following hepatitis B surface antigen loss: A multi-site study by the Canadian Hepatitis B Network.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vienneau Jordyn, Ko Hin Hin, Cooper Curtis L, Doucette Karen E, Elkashab Magdy, Ramji Alnoor, Tam Edward, Fung Scott K, Crotty Pam, Coffin Carla S
Аннотация
BACKGROUND: Chronic hepatitis B (CHB) imposes adverse health outcomes but may also cause psychosocial and quality-of-life (QOL) challenges. Hepatitis B surface antigen (HBsAg) loss, whether spontaneous or due to treatment (ie, a functional cure), is associated with improved clinical outcomes, but the impact of HBsAg clearance on patient-reported outcome measures (PROMs) is poorly understood.
METHODS: Two surveys (hepatitis B self-stigma and hepatitis B-related QOL [HBQOL]) were administered to adults with a history of CHB with documented HBsAg clearance from six Canadian hepatology clinics.
RESULTS: Eighty-four participants were enrolled (median age: 60 years; 53.6% male). Nearly three quarters (72.6%) of patients reported never feeling self-stigma. HBQOL scores improved across all six domains (p < 0.001 for each), with the largest relative gains in psychological well-being (60% reduction), transmission concerns (55%), and stigma (53%).
CONCLUSIONS: HBsAg loss was associated with significant improvements in patient-reported stigma and QOL. These findings highlight the importance of incorporating PROMs into hepatitis B virus clinical care to better capture treatment experiences.
METHODS: Two surveys (hepatitis B self-stigma and hepatitis B-related QOL [HBQOL]) were administered to adults with a history of CHB with documented HBsAg clearance from six Canadian hepatology clinics.
RESULTS: Eighty-four participants were enrolled (median age: 60 years; 53.6% male). Nearly three quarters (72.6%) of patients reported never feeling self-stigma. HBQOL scores improved across all six domains (p < 0.001 for each), with the largest relative gains in psychological well-being (60% reduction), transmission concerns (55%), and stigma (53%).
CONCLUSIONS: HBsAg loss was associated with significant improvements in patient-reported stigma and QOL. These findings highlight the importance of incorporating PROMs into hepatitis B virus clinical care to better capture treatment experiences.